Endocrine Abstracts

High grade pancreatic NETs are usually non-functional. Here, we report a case of a patient with a high grade pancreatic NET, which was initially non-functional but became functional after chemotherapy. He was initiated on a flash glucose monitoring device (FreeStyle Libre®) avoiding the need for frequent capillary blood glucose monitoring. Using this novel approach, we demonstrated an improvement in his disabling hypoglycaemia with medical treatment. A 45-year-old profess...

An increased understanding of the genetic changes leading to thyroid cancers in recent years has led to a rapid increase in the number of effective targeted systemic therapies available for patients with advanced thyroid cancer. The multi-kinase inhibitors were the first drugs to show significant benefit but more recently more specific inhibitors of RET, BRAF, MEK and NTRK have been developed and are showing great promise. In this session I will discuss this paradigm shift in ...

Introduction: With the advent of specific gene targeted therapies for advanced thyroid cancers it has become important that molecular genetic testing is requested to identify patients suitable for these treatments, for example with BRAF, RET or NTRK inhibitors. We investigated the proportion of patients with advanced thyroid cancer in a specialist thyroid cancer clinic who had undergone appropriate testing.Participants and Method...

Introduction: Carcinoid crisis represents a rare medical emergency with potentially fatal manifestations that can occur in patients with neuroendocrine tumours (NETs). The condition is caused by a substantial release of vasoactive metabolites from the NETs during diagnostic or therapeutic interventions. However, in rare instances, it can occur spontaneously. Here, we report a patient who developed a carcinoid crisis following radioactive iodine131I (RAI) treatment f...

Pancreatic neuroendocrine tumours are rare with an incidence of 5 per million. Of these tumours, 75% maybe hormonally functioning. They carry a better prognosis than adenocarcinoma of the pancreas. Parathyroid Hormone related peptide hypersecretion in PNETs is uncommon and is solely associated with metastatic PNETs. 31 cases are reported of PTH-rPoma in the literature. Here we describe a novel case presenting with cough. A previously well 56-year-old female presented to the ac...

Background: Papillary thyroid cancer is the commonest thyroid malignancy. Surgery is first-line treatment, followed by radioiodine and long-term, high dose levothyroxine to suppress TSH.Cortisol is known to suppress TSH secretion by the pituitary, although the mechanism remains unclear. Correspondingly, hypocortisolism may raise TSH levels.Case Summary: A 64 year old woman presented with a right-sided thyroid nodule, normal TSH and...

: The orally administered targeted therapies, Sunitinib and Everolimus lengthen progression free survival in pancreatic neuroendocrine tumours (pNETs). Choice of therapy has traditionally been on avoidance of deterioration in established co-morbidities. Sunitinib has been recognised to induce hypocalcaemia and the subsequent need for calcium supplementation has been reported. However, little has been documented about the utility and therapeutic significance of this effect....

Introduction: Lutetium-177 Oxodotreotide (Lutathera) is a targeted molecular radiotherapy treatment for advanced, inoperable, progressive neuro-endocrine tumours. We present our experience of Lutathera therapy with particular focus on our experience implementing treatment as a day-case procedure, and assessment of adherence to treatment quality standards surrounding the administration.Aims: To assess safety of Lutathera as a day-case treatment.<p cla...